CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
A PHASE1/PHASE2 clinical study on Large B-cell Lymphoma, this trial is completed. The trial is conducted by Institute of Hematology & Blood Diseases Hospital, China and has accumulated 10 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Hematology & Blood Diseases Hospital, China
- Juventas Cell Therapy Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .